Exscientia PLC
NASDAQ:EXAI

Watchlist Manager
Exscientia PLC Logo
Exscientia PLC
NASDAQ:EXAI
Watchlist
Price: 5.58 USD -0.53%
Market Cap: 721.3m USD
Have any thoughts about
Exscientia PLC?
Write Note

Intrinsic Value

EXAI's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one EXAI stock under the Base Case scenario is 5.2 USD. Compared to the current market price of 5.58 USD, Exscientia PLC is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EXAI Intrinsic Value
5.2 USD
Overvaluation 7%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Exscientia PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for EXAI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about EXAI?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Exscientia PLC

Provide an overview of the primary business activities
of Exscientia PLC.

What unique competitive advantages
does Exscientia PLC hold over its rivals?

What risks and challenges
does Exscientia PLC face in the near future?

Summarize the latest earnings call
of Exscientia PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Exscientia PLC.

Provide P/S
for Exscientia PLC.

Provide P/E
for Exscientia PLC.

Provide P/OCF
for Exscientia PLC.

Provide P/FCFE
for Exscientia PLC.

Provide P/B
for Exscientia PLC.

Provide EV/S
for Exscientia PLC.

Provide EV/GP
for Exscientia PLC.

Provide EV/EBITDA
for Exscientia PLC.

Provide EV/EBIT
for Exscientia PLC.

Provide EV/OCF
for Exscientia PLC.

Provide EV/FCFF
for Exscientia PLC.

Provide EV/IC
for Exscientia PLC.

Show me price targets
for Exscientia PLC made by professional analysts.

What are the Revenue projections
for Exscientia PLC?

How accurate were the past Revenue estimates
for Exscientia PLC?

What are the Net Income projections
for Exscientia PLC?

How accurate were the past Net Income estimates
for Exscientia PLC?

What are the EPS projections
for Exscientia PLC?

How accurate were the past EPS estimates
for Exscientia PLC?

What are the EBIT projections
for Exscientia PLC?

How accurate were the past EBIT estimates
for Exscientia PLC?

Compare the revenue forecasts
for Exscientia PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Exscientia PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Exscientia PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Exscientia PLC compared to its peers.

Compare the P/E ratios
of Exscientia PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Exscientia PLC with its peers.

Analyze the financial leverage
of Exscientia PLC compared to its main competitors.

Show all profitability ratios
for Exscientia PLC.

Provide ROE
for Exscientia PLC.

Provide ROA
for Exscientia PLC.

Provide ROIC
for Exscientia PLC.

Provide ROCE
for Exscientia PLC.

Provide Gross Margin
for Exscientia PLC.

Provide Operating Margin
for Exscientia PLC.

Provide Net Margin
for Exscientia PLC.

Provide FCF Margin
for Exscientia PLC.

Show all solvency ratios
for Exscientia PLC.

Provide D/E Ratio
for Exscientia PLC.

Provide D/A Ratio
for Exscientia PLC.

Provide Interest Coverage Ratio
for Exscientia PLC.

Provide Altman Z-Score Ratio
for Exscientia PLC.

Provide Quick Ratio
for Exscientia PLC.

Provide Current Ratio
for Exscientia PLC.

Provide Cash Ratio
for Exscientia PLC.

What is the historical Revenue growth
over the last 5 years for Exscientia PLC?

What is the historical Net Income growth
over the last 5 years for Exscientia PLC?

What is the current Free Cash Flow
of Exscientia PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Exscientia PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Exscientia PLC

Current Assets 404.9m
Cash & Short-Term Investments 361.2m
Receivables 35.9m
Other Current Assets 7.9m
Non-Current Assets 105.8m
Long-Term Investments 3m
PP&E 67.5m
Intangibles 34.6m
Other Non-Current Assets 663k
Current Liabilities 65.1m
Accounts Payable 11.3m
Accrued Liabilities 22.2m
Other Current Liabilities 31.5m
Non-Current Liabilities 89.9m
Long-Term Debt 16.5m
Other Non-Current Liabilities 73.4m
Efficiency

Earnings Waterfall
Exscientia PLC

Revenue
21m GBP
Cost of Revenue
-27.8m GBP
Gross Profit
-6.8m GBP
Operating Expenses
-142.4m GBP
Operating Income
-149.2m GBP
Other Expenses
19.6m GBP
Net Income
-129.6m GBP

Free Cash Flow Analysis
Exscientia PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q1 2024, Exscientia achieved a 29% reduction in cash burn, extending its cash runway into 2027. The company anticipates significant milestones with its clinical pipeline, particularly with CDK7 and LSD1 inhibitors, which are expected to deliver data later this year. The automation lab, now fully operational, significantly reduces costs and accelerates discovery processes. Strategic partnerships with firms like Sanofi and Merck are anticipated to generate hundreds of millions in milestones. By cutting 20-25% of global staff, the company will realize $40 million in annualized savings starting in 2025 .

What is Earnings Call?
Fundamental Scores

EXAI Profitability Score
Profitability Due Diligence

Exscientia PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
16/100
Profitability
Score

Exscientia PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

EXAI Solvency Score
Solvency Due Diligence

Exscientia PLC's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
59/100
Solvency
Score

Exscientia PLC's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EXAI Price Targets Summary
Exscientia PLC

Wall Street analysts forecast EXAI stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EXAI is 5.46 USD with a low forecast of 5.05 USD and a high forecast of 5.99 USD.

Lowest
Price Target
5.05 USD
9% Downside
Average
Price Target
5.46 USD
2% Downside
Highest
Price Target
5.99 USD
7% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for EXAI?

Click here to dive deeper.

Dividends

Exscientia PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for EXAI is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

EXAI News

Other Videos

Profile

Exscientia PLC Logo
Exscientia PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

696.4m USD

Dividend Yield

0%

Description

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.

Contact

OXFORDSHIRE
Oxford
The Schrodinger Building, Oxford Science Park
+441865818941.0
www.exscientia.ai

IPO

2021-10-01

Employees

208

Officers

Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
Dr. David Hallett Ph.D.
CFO, Chief Strategy Officer & Executive Director
Mr. Ben R. Taylor
Chief Technology Officer
Dr. John P. Overington Ph.D.
Vice President of Investor Relations
Ms. Sara Sherman
Executive VP of Legal & Company Secretary
Mr. Dan Ireland
Executive Vice President of Corporate Development
Mr. Parker Moss
Show More
Chief People Officer
Ms. Caroline Rowland
Chief Business Officer
Mr. Richard Law
Executive Vice President of Precision Medicine
Mr. Nikolaus Krall
Interim Chief Medical Officer & Clinical Development Lead
Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one EXAI stock?

The intrinsic value of one EXAI stock under the Base Case scenario is 5.2 USD.

Is EXAI stock undervalued or overvalued?

Compared to the current market price of 5.58 USD, Exscientia PLC is Overvalued by 7%.

Back to Top